- Immatics reported updated Phase 1 data for its PRAME programs at ESMO 2026, with IMA402 and IMA203CD8 showing objective responses, disease control and manageable safety profiles in heavily pretreated solid tumor patients, including melanoma and ovarian cancer.
- The breadth of activity across multiple PRAME expressing tumors and the durability of some responses, extending beyond 2 years, highlight how central PRAME targeted therapies could become to Immatics operating focus and clinical investment.
- We will now look at how Immatics' investment narrative could be influenced by the response rates and tolerability profile of the PRAME programs.
Scan PRAME focused oncology opportunities beyond Immatics with a curated set of 34 healthcare AI stocks that could be building similarly focused pipelines off the market's radar.
What Is Immatics' Investment Narrative?
To be a shareholder in Immatics, you have to believe the PRAME franchise can justify years of high R&D spend and ongoing losses. The fresh IMA402 and IMA203CD8 data tighten that story. Objective responses in heavily pretreated solid tumors, plus manageable safety, give the pipeline more substance and help explain why analysts still model rapid revenue expansion even as the stock has fallen about 30% year to date.
The flip side is that the business is still small, with about €41.7m in revenue and a net loss above €200m, funded entirely through higher risk external capital. These ESMO readouts reset near term catalysts around further PRAME updates, potential partnerships and funding steps more than around current sales or pricing. Execution now is about running larger trials cleanly, securing cash on acceptable terms and keeping the valuation gap versus a 21.4x P/S multiple from widening further.
Yet there is one structural issue in the Immatics story that this positive PRAME update does nothing to resolve...
There's only one way to know the right time to buy, sell or hold Immatics. Head to Simply Wall St's company report for the latest analysis of Immatics's Fair Value.
Exploring Other Perspectives
Fair value estimates for Immatics from the Simply Wall St Community span a wide band, from about 0.06 to 17.26, across 2 individual viewpoints. That gap shows how differently private investors can price the same pipeline. Updated PRAME data released after those forecasts could shift expectations, so you may want to review several fresh opinions.
Explore another Immatics fair value estimate, including one that suggests as much as 99% downside from the current price!
Form Your Own Verdict
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Immatics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Immatics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Immatics' overall financial health at a glance.
Looking For More Investment Ideas Beyond Immatics?
Once you have a view on Immatics, it can help to set it in context by comparing it with other businesses that fit different risk and quality profiles using the Simply Wall St screener.
- For investors who want quality at a discount, scan a 27 high quality undervalued stocks that may combine strong fundamentals with prices that have not caught up yet.
- If capital preservation is front of mind, filter for 30 resilient stocks with low risk scores that score well on financial stability and business risk.
- To uncover potential outliers before they become widely followed, browse a 21 high quality undiscovered gems that pair solid financials with relatively low market attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com